Blood pressure control, drug therapy, and kidney disease

Gabriel Contreras, Tom Greene, Lawrence Y. Agodoa, DeAnna Cheek, George Junco, Donna Dowie, James Lash, Michael Lipkowitz, Edgar R. Miller, Akinlou Ojo, Mohammed Sika, Beth Wilkening, Robert D. Toto

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The African American Study of Kidney Disease and Hypertension examined the effect on renal function decline of 2 blood pressure (BP) goals (low mean arterial pressure [MAP] S92 versus usual MAP 102 to 107 mm Hg) and 3 antihypertensives (ramipril versus amlodipine versus metoprolol). We previously reported that in all drug groups combined the BP intervention had similar effects on the primary outcome of glomerular filtration rate (GFR) slope or the main secondary clinical composite outcome of end-stage renal disease (ESRD), death, or GFR decline by 50% or 25 mL/min per 1.73 m 2. This report examines the effect of the BP intervention separately in the 3 drug groups. The BP effect was similar among the drug groups for either GFR slope or the main clinical composite. However, the BP effect differed significantly among the drug groups for the composite of ESRD or death (P=0.035) and ESRD alone (P=0.021). Higher event rates for amlodipine patients assigned to the usual BP goal (0.087 per patient-year for ESRD or death and 0.064 per patient-year for ESRD) were seen compared with the remaining groups of the factorial design (range, 0.041 to 0.050 for ESRD or death; and range, 0.027 to 0.036 for ESRD). The low BP goal was associated with reduced risk of ESRD or death (risk reduction 51%; 95% confidence interval, 13% to 73%) and ESRD (54%; 8% to 77%) for amlodipine patients, but not for patients assigned to the other drug groups. These secondary analyses suggest a benefit of the low BP goal among patients assigned to amlodipine, but they must be interpreted cautiously.

Original languageEnglish (US)
Pages (from-to)44-50
Number of pages7
JournalHypertension
Volume46
Issue number1
DOIs
StatePublished - Jul 2005

Fingerprint

Kidney Diseases
Chronic Kidney Failure
Blood Pressure
Drug Therapy
Amlodipine
Glomerular Filtration Rate
Hypotension
Pharmaceutical Preparations
Arterial Pressure
Ramipril
Metoprolol
Risk Reduction Behavior
African Americans
Antihypertensive Agents
Confidence Intervals
Hypertension
Kidney

Keywords

  • Angiotensin converting enzyme
  • Calcium channel blockers
  • Hypertension
  • Renal disease

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Contreras, G., Greene, T., Agodoa, L. Y., Cheek, D., Junco, G., Dowie, D., ... Toto, R. D. (2005). Blood pressure control, drug therapy, and kidney disease. Hypertension, 46(1), 44-50. https://doi.org/10.1161/01.HYP.0000166746.04472.60

Blood pressure control, drug therapy, and kidney disease. / Contreras, Gabriel; Greene, Tom; Agodoa, Lawrence Y.; Cheek, DeAnna; Junco, George; Dowie, Donna; Lash, James; Lipkowitz, Michael; Miller, Edgar R.; Ojo, Akinlou; Sika, Mohammed; Wilkening, Beth; Toto, Robert D.

In: Hypertension, Vol. 46, No. 1, 07.2005, p. 44-50.

Research output: Contribution to journalArticle

Contreras, G, Greene, T, Agodoa, LY, Cheek, D, Junco, G, Dowie, D, Lash, J, Lipkowitz, M, Miller, ER, Ojo, A, Sika, M, Wilkening, B & Toto, RD 2005, 'Blood pressure control, drug therapy, and kidney disease', Hypertension, vol. 46, no. 1, pp. 44-50. https://doi.org/10.1161/01.HYP.0000166746.04472.60
Contreras G, Greene T, Agodoa LY, Cheek D, Junco G, Dowie D et al. Blood pressure control, drug therapy, and kidney disease. Hypertension. 2005 Jul;46(1):44-50. https://doi.org/10.1161/01.HYP.0000166746.04472.60
Contreras, Gabriel ; Greene, Tom ; Agodoa, Lawrence Y. ; Cheek, DeAnna ; Junco, George ; Dowie, Donna ; Lash, James ; Lipkowitz, Michael ; Miller, Edgar R. ; Ojo, Akinlou ; Sika, Mohammed ; Wilkening, Beth ; Toto, Robert D. / Blood pressure control, drug therapy, and kidney disease. In: Hypertension. 2005 ; Vol. 46, No. 1. pp. 44-50.
@article{dc9f8f7a3acc40a5828c31796bec8f42,
title = "Blood pressure control, drug therapy, and kidney disease",
abstract = "The African American Study of Kidney Disease and Hypertension examined the effect on renal function decline of 2 blood pressure (BP) goals (low mean arterial pressure [MAP] S92 versus usual MAP 102 to 107 mm Hg) and 3 antihypertensives (ramipril versus amlodipine versus metoprolol). We previously reported that in all drug groups combined the BP intervention had similar effects on the primary outcome of glomerular filtration rate (GFR) slope or the main secondary clinical composite outcome of end-stage renal disease (ESRD), death, or GFR decline by 50{\%} or 25 mL/min per 1.73 m 2. This report examines the effect of the BP intervention separately in the 3 drug groups. The BP effect was similar among the drug groups for either GFR slope or the main clinical composite. However, the BP effect differed significantly among the drug groups for the composite of ESRD or death (P=0.035) and ESRD alone (P=0.021). Higher event rates for amlodipine patients assigned to the usual BP goal (0.087 per patient-year for ESRD or death and 0.064 per patient-year for ESRD) were seen compared with the remaining groups of the factorial design (range, 0.041 to 0.050 for ESRD or death; and range, 0.027 to 0.036 for ESRD). The low BP goal was associated with reduced risk of ESRD or death (risk reduction 51{\%}; 95{\%} confidence interval, 13{\%} to 73{\%}) and ESRD (54{\%}; 8{\%} to 77{\%}) for amlodipine patients, but not for patients assigned to the other drug groups. These secondary analyses suggest a benefit of the low BP goal among patients assigned to amlodipine, but they must be interpreted cautiously.",
keywords = "Angiotensin converting enzyme, Calcium channel blockers, Hypertension, Renal disease",
author = "Gabriel Contreras and Tom Greene and Agodoa, {Lawrence Y.} and DeAnna Cheek and George Junco and Donna Dowie and James Lash and Michael Lipkowitz and Miller, {Edgar R.} and Akinlou Ojo and Mohammed Sika and Beth Wilkening and Toto, {Robert D.}",
year = "2005",
month = "7",
doi = "10.1161/01.HYP.0000166746.04472.60",
language = "English (US)",
volume = "46",
pages = "44--50",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Blood pressure control, drug therapy, and kidney disease

AU - Contreras, Gabriel

AU - Greene, Tom

AU - Agodoa, Lawrence Y.

AU - Cheek, DeAnna

AU - Junco, George

AU - Dowie, Donna

AU - Lash, James

AU - Lipkowitz, Michael

AU - Miller, Edgar R.

AU - Ojo, Akinlou

AU - Sika, Mohammed

AU - Wilkening, Beth

AU - Toto, Robert D.

PY - 2005/7

Y1 - 2005/7

N2 - The African American Study of Kidney Disease and Hypertension examined the effect on renal function decline of 2 blood pressure (BP) goals (low mean arterial pressure [MAP] S92 versus usual MAP 102 to 107 mm Hg) and 3 antihypertensives (ramipril versus amlodipine versus metoprolol). We previously reported that in all drug groups combined the BP intervention had similar effects on the primary outcome of glomerular filtration rate (GFR) slope or the main secondary clinical composite outcome of end-stage renal disease (ESRD), death, or GFR decline by 50% or 25 mL/min per 1.73 m 2. This report examines the effect of the BP intervention separately in the 3 drug groups. The BP effect was similar among the drug groups for either GFR slope or the main clinical composite. However, the BP effect differed significantly among the drug groups for the composite of ESRD or death (P=0.035) and ESRD alone (P=0.021). Higher event rates for amlodipine patients assigned to the usual BP goal (0.087 per patient-year for ESRD or death and 0.064 per patient-year for ESRD) were seen compared with the remaining groups of the factorial design (range, 0.041 to 0.050 for ESRD or death; and range, 0.027 to 0.036 for ESRD). The low BP goal was associated with reduced risk of ESRD or death (risk reduction 51%; 95% confidence interval, 13% to 73%) and ESRD (54%; 8% to 77%) for amlodipine patients, but not for patients assigned to the other drug groups. These secondary analyses suggest a benefit of the low BP goal among patients assigned to amlodipine, but they must be interpreted cautiously.

AB - The African American Study of Kidney Disease and Hypertension examined the effect on renal function decline of 2 blood pressure (BP) goals (low mean arterial pressure [MAP] S92 versus usual MAP 102 to 107 mm Hg) and 3 antihypertensives (ramipril versus amlodipine versus metoprolol). We previously reported that in all drug groups combined the BP intervention had similar effects on the primary outcome of glomerular filtration rate (GFR) slope or the main secondary clinical composite outcome of end-stage renal disease (ESRD), death, or GFR decline by 50% or 25 mL/min per 1.73 m 2. This report examines the effect of the BP intervention separately in the 3 drug groups. The BP effect was similar among the drug groups for either GFR slope or the main clinical composite. However, the BP effect differed significantly among the drug groups for the composite of ESRD or death (P=0.035) and ESRD alone (P=0.021). Higher event rates for amlodipine patients assigned to the usual BP goal (0.087 per patient-year for ESRD or death and 0.064 per patient-year for ESRD) were seen compared with the remaining groups of the factorial design (range, 0.041 to 0.050 for ESRD or death; and range, 0.027 to 0.036 for ESRD). The low BP goal was associated with reduced risk of ESRD or death (risk reduction 51%; 95% confidence interval, 13% to 73%) and ESRD (54%; 8% to 77%) for amlodipine patients, but not for patients assigned to the other drug groups. These secondary analyses suggest a benefit of the low BP goal among patients assigned to amlodipine, but they must be interpreted cautiously.

KW - Angiotensin converting enzyme

KW - Calcium channel blockers

KW - Hypertension

KW - Renal disease

UR - http://www.scopus.com/inward/record.url?scp=21744448809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21744448809&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.0000166746.04472.60

DO - 10.1161/01.HYP.0000166746.04472.60

M3 - Article

C2 - 15897360

AN - SCOPUS:21744448809

VL - 46

SP - 44

EP - 50

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 1

ER -